logo

Loading..
Svenska
  • Home
  • About us
    About us
      • About BioArctic
      • CEO Gunilla Osswald presents BioArctic
      • Vision, mission and business concept
      • Culture and values
      • Objective and strategy
      • Collaborations and partners
      • Sustainability
        • Code of Conduct
        • Work environment
        • Diversity
      • Organization
        • Board of directors
        • Senior management
        • Senior scientific advisors
        • Scientific advisory boards
      • History
  • Research and development
    Research and development
      • Technology
      • Project portfolio
      • Focus Areas
        • Alzheimer´s disease
        • Parkinson’s disease
        • Other CNS disorders
        • Blood-brain barrier technology
        • Diagnostics
  • Governance
    Governance
      • Governance structure
      • Corporate Governance Reports
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • Board of Directors
        • Board Committees
        • Work of the Board of Directors
      • Senior management
      • Remuneration
      • Internal audit and control
      • Audit
      • Articles of Association
  • Investors
    Investors
      • The share
        • Share capital development
        • Dividend
        • Ownership structure
        • Analysts
      • Financial reports
      • Prospectus
      • Presentations
      • Press releases
      • News
      • Calendar
      • Privacy policy - Shareholders
      • Subscribe
      • Contact
  • Media
    Media
      • Press releases
      • News
      • Image bank
      • Subscribe
      • Contacts
  • Career
    Career
      • Career
      • Job openings
      • Open application
  • Contacts
    Contacts
      • Office
      • Investors
      • Media
Svenska
July 9, 2021

Interim report January – June 2021

FDA grants Breakthrough Therapy designation for lecanemab

Documents

  • Presentation – Interim Report January – June 2021 English July 9, 2021

Links

  • Report
  • Webcast

Calendar

  • October 21, 2021Interim report January – September 2021
  • February 3, 2022Full Year Report 2021
More events

Subscribe

Read more about how we protect your personal data.
  • Investors
    • The share
      • Share capital development
      • Dividend
      • Ownership structure
      • Analysts
    • Financial reports
    • Prospectus
    • Presentations
    • Press releases
    • News
    • Calendar
    • Privacy policy – Shareholders
    • Subscribe
    • Contact
Oskar Bosson
Oskar Bosson
Vice President Communications & IR
oskar.bosson@bioarctic.se
+46704107180
About us
  • About BioArctic
  • CEO Gunilla Osswald presents BioArctic
  • Vision, mission and business concept
  • Culture and values
  • Objective and strategy
  • Collaborations and partners
  • Sustainability
  • Organization
  • History
Research and development
  • Technology
  • Project portfolio
  • Focus Areas
Governance
  • Governance structure
  • Corporate Governance Reports
  • General Meeting
  • Nomination Committee
  • Board of Directors
  • Senior management
  • Remuneration
  • Internal control
  • Audit
  • Articles of Association
Investors
  • The share
  • Financial reports
  • Prospectus
  • Presentations
  • Press releases
  • News
  • Calendar
  • Privacy policy – Shareholders
  • Subscribe
  • Contact
Media
  • Press releases
  • News
  • Image bank
  • Subscribe
  • Contacts
Career
  • Career
  • Job openings
  • Open application
Contacts
  • Office
  • Investors
  • Media

BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. Phone: +46 8 695 69 30. E-mail: info@bioarctic.se. Registration number: 556601-2679.

© 2021 BioArctic AB – All rights reserved

  • About Cookies
  • Processing of personal data